COPENHAGEN, Denmark — In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses results from the phase 3 PRESERVE-003 trial, which were presented at European Lung Cancer Congress.
The randomized trial compared gotistobart (BNT316/ONC-392; BioNTech, OncoC4), a novel anti-CTLA-4 antibody, with docetaxel among patients with metastatic squamous non-small cell lung cancer who had progressed on immunotherapy and chemotherapy.
“This was very positive,” said Cooper, noting better objective response rate and 12-month PFS and OS in the gotistobart arm.

Results published in JAMA Network Open showed older adults with a fall-related hip fracture spent fewer days at home 12 months after the fracture if they lived in an economically deprived area.
“The overall take home message of the study is that your ZIP code might matter just as much as your genetic code for outcomes after hip fracture,” Jason R. Falvey, PT, DPT, PhD, associate professor in the department of physical therapy and rehabilitation science and the department of epidemiology and public health, as well as director of University of Maryland School of Medicine’s

Sometimes, it seems like eyes never get a break from screens.
From work to school to relaxing at home, Healio | OSN Cornea/External Disease Section Editor Preeya K. Gupta, MD, said it is not uncommon for people to have almost uninterrupted exposure to screens throughout their day. While screens might be unavoidable in modern life, ophthalmologists who see children and adults have to deal with the consequences of this digital lifestyle.
“As a society, we’ve decided that digital devices are our primary mode of communication and interpretation,” Gupta said. “I hear it day in and day out from

A GLP-1/glucagon dual agonist induced up to 16.6% weight loss at 76 weeks for adults with overweight or obesity and without type 2 diabetes, according to topline results from the SYNCHRONIZE-1 trial.
Survodutide (Boehringer Ingelheim, Zealand Pharma) is a once-weekly injectable medication currently under investigation for the treatment of overweight or obesity as well as metabolic dysfunction-associated steatohepatitis or fibrosis. In SYNCHRONIZE-1, adults with overweight or obesity were randomly assigned to once-weekly survodutide 3.6 mg or 6 mg, or placebo for 76 weeks. The primary endpoints

Electronic provider notifications may close gaps in referral for treatment of severe aortic stenosis compared with usual care among older patients, a speaker reported.
The notification system increased the odds of surgical and transcatheter aortic valve replacement, with the likelihood of treatment increasing with patient age, according to a DETECT-AS subanalysis presented at the Society for Cardiovascular Angiography & Interventions Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention Summit.
“There’s high

LAS VEGAS — Adults with classic congenital adrenal hyperplasia experienced substantial and sustained reductions in glucocorticoid doses with 2 years of crinecerfont therapy, reducing treatment burden with no new safety signals observed.
New open-label extension data from the CAHtalyst trial, presented at the American Association of Clinical Endocrinology Annual Scientific and Clinical Conference, also showed that approximately 70% of participants receiving crinecerfont (Crenessity, Neurocrine Biosciences) reached physiologic-range glucocorticoid dosing at 2 years, with 75% of participants

Cancer risks were significantly greater for residents of British Columbia, Canada, who had biopsy-proven glomerular disease compared with the general population, according to study data published in the American Journal of Kidney Diseases.
Previous data evaluating cancer risks for patients with glomerular diseases have faced data limitations, according to Jialin Han, PhD, MSc, in the department of medicine, division of nephrology at University of British Columbia, Canada, and colleagues. Understanding and quantifying cancer risks among these patients could help identify risks earlier, they

Commercialization of Palforzia, the first FDA-approved peanut allergy oral immunotherapy, will be discontinued at the end of July, according to the treatment’s website.
This note on Palforzia’s (Peanut [Arachis hypogaea] Allergen Powder-dnfp) website comes from the manufacturer, Stallergenes Greer, and outlines that product safety, quality or efficacy were not related to this decision.
In a statement Stallergenes Greer shared with Healio, the company said, “the complex administrative and dosing requirements have contributed to limited adoption in clinical practice.”
The company added that it

CHICAGO — Prolonged seizures led to work productivity loss and caused worrying and anxious/depressed feelings in patients with epilepsy and their caregivers, according to data presented at the American Academy of Neurology Annual Meeting.
“Clinicians should ask [patients] about prolonged seizures and attempt to minimize their occurrence (via avoiding triggers or giving extra medications when they occur), their severity and their effects, including through use of rescue medications, both those approved now and those in the pipeline,” Lawrence J. Hirsch, MD, codirector of the comprehensive

Researchers are exploring whether a virtual reality intervention could reduce preoperative anxiety among patients with cancer, according to information presented at Cedars-Sinai’s Virtual Medical Conference.
The virtual reality (VR) will include guided breathing, an educational platform about the operating room and more.
“The vision is being an intervention that is widely applicable to a lot of different surgeries,” Eisi Mollanji, MD, a third-year psychiatry resident at University of Manitoba, told Healio.
“Something as simple as saying, ‘You’re having surgery; here’s a headset.’ Here’s an